AcuCort AB, a Swedish pharmaceutical company, has received a significant endorsement from LSIF, as the latter commits to a 1 MSEK investment irrespective of the current share price. This decision comes on the heels of two Letters of Intent (LOIs) that AcuCort has signed, notably with Glenmark Pharmaceuticals, a global player in the pharmaceutical industry.

Jan Poulsen, CEO of LSIF, expressed confidence in AcuCort's trajectory, citing the LOIs as strong indicators of the company's potential. 'We believe the current share price does not reflect the company’s true potential,' Poulsen stated, emphasizing the strategic importance of the LOI with Glenmark.

AcuCort's CEO, Jonas Jönmark, echoed this sentiment, stating that the investment will accelerate their commercial efforts. Glenmark's involvement is particularly noteworthy, given their extensive reach in the pharmaceutical sector, specializing in respiratory, dermatology, and oncology therapies.

The LOI with Glenmark, signed on June 17, 2025, covers the distribution and marketing of Zeqmelit® in six European countries, including Germany. This region represents a market with over 160 million people, aligning with AcuCort's strategy to establish a foothold in key European markets.

Additionally, through the exercise of TO 2 options, LSIF will subscribe to approximately 1.3 million new shares, further strengthening its stake in AcuCort. The exercise period for these options is from June 9 to June 20, 2025, with a subscription price of 0.75 SEK per new share.

Given these developments, investors might consider holding onto their AcuCort shares. The strategic partnership with Glenmark and the backing from LSIF highlight AcuCort's growth prospects in the lucrative European market. However, as with any investment, it is crucial to remain informed and consider potential risks.